Pmd107 - Cost-Effectiveness Analysis of Next Generation Renal Denervation Therapy Devices: Threshold Analysis and Projections of the Spyral HTN-On Med Trial for Germany

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1556
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Renal Denervation for Resistant Hypertension—the Symplicity HTN-1 Study

The Lancet
Medicine
2014English

Using “Big Data” in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

PMH81 Cost-Effectiveness Analysis of Antidepressants by the IQWIG in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension: One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial

Circulation
Cardiovascular MedicinePhysiologyCardiology
2012English

Renal Denervation in Hypertension: Is It the End or the Beginning of a SPYRAL?

Blood Pressure
Internal MedicineMedicineCardiovascular MedicineCardiology
2017English

Cv3 - Cost-Effectiveness of Sacubitril/Valsartan in Germany: Applying the Efficiency Threshold

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cytomegalovirus Screening in Pregnancy: A Cost-Effectiveness and Threshold Analysis

American Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2018English

CONGRESS COVERAGE: Renal Sympathetic Denervation for Resistant Hypertension: Symplicity HTN-3 and the Power of Placebo

Open Hypertension Journal
Cardiovascular MedicineCardiology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy